Abstract
Background: Nasopharyngeal carcinoma (NPC) is a rare malignancy with multiple risk factors (Epstein-Barr virus, etc.) that seriously threatens the health of people. CircRNAs are known to regulate the tumorigenesis of malignant tumours, including NPC. Moreover, circCRIM1 expression is reported to be upregulated in NPC. Nevertheless, the impact of circCRIM1 on NPC progression is not clear.

Methods: An MTT assay was performed to assess cell viability. In addition, cell invasion and migration were assessed by the transwell assay. Dual luciferase assays were performed to assess the association among circCRIM1, miR-34c-5p and FOSL1. Moreover, RT-qPCR was applied to assess mRNA levels, and protein levels were determined by Western blot.

Results: CircCRIM1 and FOSL1 were upregulated in NPC cells, while miR-34c-5p was downregulated. Knockdown of circCRIM1 significantly decreased the invasion, viability and migration of NPC cells. The miR-34c-5p inhibitor notably promoted the malignant behaviour of NPC cells, while miR-34c-5p mimics exerted the opposite effect. Moreover, circCRIM1 could bind with miR-34c-5p, and FOSL1 was identified to be downstream of miR-34c-5p. Furthermore, circCRIM1 downregulation notably inhibited the proliferation and invasion of NPC cells, while this phenomenon was significantly reversed by FOSL1 overexpression.

Conclusion: Silencing circCRIM1 inhibited the tumorigenesis of NPC. Thus, circCRIM1 might be a novel target for NPC.

Keywords: NPC, circCRIM1, miR-34c-5p, FOSL1
NPC cells were transfected with the miR-34c-5p mimics/inhibitor, pcDNA3.1-FOSL1 or NC (NC mimics/inhibitor or pcDNA3.1) using Lipofectamine 3000. The miR-34c-5p mimics/inhibitor, pcDNA3.1-FOSL1 and NC were purchased from GenePharma.

**MTT assay**
NPC cells (5 × 10^3 cells/well) were treated with the NC or sh-CRIM1 for 12, 24, 48 or 72 h. After that, NPC cells were treated with MTT solution (20 µL) for 2 h. The absorbance (490 nm) was determined by a microplate reader. The protocol was performed as previously described [23].

**Western blot assay**
Cells were lysed in RIPA buffer (Beyotime). Equal amounts (20 µg) of protein from each group were separated by SDS–PAGE, and the proteins were then transferred onto a PVDF membrane (Beyotime). Then, the membrane was blocked and incubated with primary antibodies against FOSL1 (1:1000) and GAPDH (1:1000) and the corresponding secondary antibody (1:5000). All antibodies were purchased from Abcam (MA, USA). GAPDH was used for normalization. The protocol was performed as described previously [24].

**qRT-PCR**
Total RNA was obtained with TRIzol (TaKaRa). Subsequently, cDNA was synthesized with a reverse transcription kit (TaKaRa). The protocol was as follows: 94 ºC for 2 min, followed by 35 cycles of 94 ºC for 30 s and 55 ºC for 45 s. The primers were designed by GenePharma, and the data were quantified by the 2^−ΔΔCt method. β-actin or U6 was used for normalization. The following primers were designed by GenePharma: circCRIM1, forward, 5'-GCC TTTCCCTGCTACTTGTG-3' and reverse 5'-AGA GCTTCAAGGGCTAGG-3'; miR-34c-5p, forward, 5'-GTCGTATCCAGTGCAGGGTCCAGGAGGTATTTGC-3' and reverse 5'-TCCAGTGCAGGGTCCAGGAGGTATTTGC-3'; and U6, forward, 5'-AACGCTTCACGAATTTGC-3' and reverse 5'-AACGCTTCACGAATTTGC-3'.

**Materials and methods**

**Cell culture**
NP69 and human nasopharyngeal carcinoma cells (SUNE-1, CNE2, C666-1, CNE-1, HNE1 and 5-8F) were purchased from the American Type Culture Collection (ATCC) and maintained in DMEM (Thermo Fisher Scientific) containing 10% FBS, penicillin and streptomycin (1%, Thermo Fisher Scientific) at 37 ºC and 5% CO₂.

**Cell transfection**
The shRNA-directed target CRIM1 (sh-CRIM1) and negative control (sh-NC) were generated by GenePharma (Shanghai, China). Sh-CRIM1 and sh-NC were transfected into NPC cells. After incubation, the supernatant was collected by centrifugation. Then, the supernatants were filtered, and the cells were infected with particles for 48 h. Puromycin (2.5 µg/mL, Sigma, MO, USA) was applied to select the cells.

**Cell migration and invasion assays**
The upper chamber was pretreated with Matrigel (100 µL, not included in the migration assay). NPC cells (1.0 × 10^6 cells per chamber) in medium (1% FBS) were seeded into the upper chamber. Meanwhile, RPMI 1640
medium containing 10% FBS was added to the lower chamber. Subsequently, the cells in the chamber were rinsed and fixed with 5% glutaraldehyde at 4 °C. Then, the cells were stained with crystal violet (0.1%) for 20 min. The cells were observed under a microscope after the chamber was washed.

Dual luciferase reporter assay
CircCRIM1 and FOSL1 (3’-UTR) sequences with miR-34c-5p binding sites were purchased from GenePharma and cloned into the psiCHECK2 vectors (Promega) to establish circCRIM1 (WT/MUT) and FOSL1 (WT/MUT). NPC cells containing NC/miR-34c-5p mimics were treated with circCRIM1 (WT/MUT) or FOSL1 (WT/MUT). The data were acquired by the luciferase system (Promega). The protocol was performed as previously described [25].

Statistical analysis
Three independent experiments were performed for each group. In addition, all data are expressed as the mean ± standard deviation (SD). Differences were analysed by Student’s t test (only 2 groups) or one-way analysis of variance (ANOVA) followed by Tukey’s test (more than 2 groups). GraphPad Prism (version 7) was used for statistical analysis. *P < 0.05 indicated statistically significant differences.

Results
CircCRIM1 and FOSL1 were upregulated in NPC cells, while miR-34c-5p was downregulated
To elucidate the role of circCRIM1, miR-34c-5p and FOSL1 in NPC, RT-qPCR was performed. As revealed in Fig. 1A–C, the expression levels of circCRIM1 and FOSL1 in NPC cells were significantly higher than those in NP69 cells. The miR-34c-5p level in NPC cells was notably lower than that in NP69 cells (Fig. 1A).

Silencing circCRIM1 significantly inhibited the proliferation, migration and invasion of NPC cells
To assess the function of circCRIM1 in NPC, NPC cells were transfected with sh-CRIM1. Then, the efficiency was determined by RT-qPCR. The circCRIM1 levels in NPC cells were significantly decreased by sh-CRIM1, and the expression of miR-34c-5p in NPC cells was notably upregulated by circCRIM1 shRNA (Fig. 2A). In addition, circCRIM1 shRNA attenuated the viability of NPC cells (Fig. 2B). Moreover, silencing circCRIM1 notably suppressed the invasion and migration of NPC cells (Fig. 2C). Altogether, these results demonstrated that silencing circCRIM1 attenuated the migration, proliferation and invasion of NPC cells.

Overexpression of miR-34c-5p alleviated the invasion, proliferation and migration of NPC cells
To assess the effect of miR-34c-5p on NPC cell growth, NPC cells were transfected with miR-34c-5p mimics/inhibitor. As shown in Fig. 3A, the level of miR-34c-5p in NPC cells was notably upregulated by miR-34c-5p but decreased by the miR-34c-5p inhibitor. Moreover, the expression of FOSL1 in cells was markedly upregulated by the miR-34c-5p inhibitor, while miR-34c-5p mimics obviously inhibited FOSL1 levels (Fig. 3B). Additionally, miR-34c-5p upregulation notably inhibited the viability of NPC cells, while miR-34c-5p downregulation exerted the opposite effect (Fig. 3C). Moreover, NPC cell invasion and migration were significantly decreased by miR-34c-5p mimics but increased by miR-34c-5p depletion.
In summary, overexpression of miR-34c-5p significantly inhibited the invasion, proliferation and migration of NPC cells.

MiR-34c-5p was shown to bind circCRIM1 and FOSL1 in NPC cells

To assess the relationship between miR-34c-5p and circCRIM1 in NPC cells, the dual luciferase assay was performed. As shown in Fig. 4A, circCRIM1 had putative miR-34c-5p binding sites, and the luciferase activity of WT-circCRIM1 was significantly downregulated by miR-34c-5p upregulation. However, miR-34c-5p had a very limited effect on the luciferase activity of MUT-circCRIM1 (Fig. 4A). Moreover, FOSL1 was predicted to be the downstream target of miR-34c-5p, and miR-34c-5p mimics notably inhibited the luciferase activity of WT-FOSL1 (Fig. 4B). Taken together, these results showed that miR-34c-5p could bind with circCRIM1 and FOSL1 in NPC.

FOSL1 upregulation reversed the circCRIM1 shRNA-induced inhibition of NPC cell invasion, proliferation and migration

To elucidate the role of FOSL1 in circCRIM1 shRNA-mediated NPC progression, NPC cells were transfected...
He et al. European Journal of Medical Research (2022) 27:59

with pcDNA3.1-FOSL1. As shown in Fig. 5A and B, the FOSL1 levels in NPC cells were decreased by circ-CRIM1 shRNA, while the effect of sh-CRIM1 on FOSL1 expression was restored by FOSL1 overexpression. In addition, the circ-CRIM1 shRNA-induced decrease in NPC cell viability was significantly abolished by FOSL1 (Fig. 5C). Consistently, the migration and invasion of circ-CRIM1 shRNA-treated NPC cells were obviously increased by the upregulation of FOSL1 (Fig. 5D). In summary, overexpression of FOSL1 reversed the circ-CRIM1 shRNA-induced downregulation of NPC cell invasion, proliferation and migration.

Discussion

NPC treatments often fail due to NPC metastasis [26, 27]. In this study, circ-CRIM1 was found to be upregulated in NPC cells, and silencing circ-CRIM1 attenuated the invasion, proliferation and migration of NPC cells. Circ-CRIM1 knockdown can reportedly alleviate the tumorigenesis of NPC [12]. In addition, our research suggested that circ-CRIM1 binds with miR-34c-5p in NPC cells, and FOSL1 was identified to be downstream of miR-34c-5p in NPC cells. Therefore, our study first explored the relationship among circ-CRIM1, miR-34c-5p and FOSL1 in NPC cells.
Fig. 4 MiR-34c-5p was shown to bind circCRIM1 and FOSL1 in NPC cells. A The binding sites between circCRIM1 and miR-34c-5p are shown. The luciferase activity of WT/MUT-circCRIM1 was determined by the dual luciferase assay. B The binding sites between miR-34c-5p and FOSL1 are shown. The luciferase activity of WT/MUT-FOSL1 was determined by the dual luciferase assay. **P < 0.05. All data are expressed as the mean ± standard deviation (SD).

Fig. 5 Overexpression of FOSL1 reversed the circCRIM1 shRNA-induced inhibition of NPC cell invasion, proliferation and migration. SUNE-1 or CNE2 cells were treated with the control, sh-NC, sh-circCRIM1, sh-NC + FOSL1 or sh-circCRIM1 + FOSL1. Then, A the circCRIM1, miR-34c-p and FOSL1 levels in NPC cells were determined by RT–qPCR. B The FOSL1 levels in NPC cells were determined by Western blot. GAPDH was used for normalization. C NPC cell viability was assessed by the MTT assay. D NPC cell invasion and migration were assessed by the transwell assay. **P < 0.01. All data are expressed as the mean ± standard deviation (SD).
It has been reported that circRNAs can regulate cellular processes, enabling them to thereby regulate the progression of multiple diseases, including cancers [28, 29]. Previous studies have indicated that circCRIM1 plays a role in malignant tumours. For example, silencing circCRIM1 disrupted osteosarcoma cell invasion, proliferation and migration via mediation of the miR-432-5p/HDAC4 axis [30]. Our research suggested an association between circCRIM1 and the miR-34c-5p/FOSL1 axis, which further supports its role in NPC. MiR-34c-5p is a key inhibitor of cancer progression [31, 32]. Previous studies suggested that silencing circCRIM1 attenuates the progression of NPC via its binding to miR-34c-5p. Moreover, Hong et al. suggested that FOXQ1 is upregulated by circCRIM1 in NPC [12], in contrast to our findings. FOXQ1 was reported to promote cell growth [33]. Thus, the similar functions of FOSL1 and FOXQ1 might account for the various functions of circCRIM1 in NPC. The above results suggest that circCRIM1 promotes NPC.

A previous study demonstrated that c-Myc and Notch1 are potentially direct targets of miR-34c-5p [10, 18]. FOSL1 reportedly participates in cancer tumorigenesis. For instance, FOSL1 upregulation led to the tumorigenesis of head and neck squamous cell carcinoma [34], and FOXQ1 promoted the proliferation of colorectal cancer cells [35]. Consistently, the results of our study further suggest that FOSL1 is the target of miR-34c-5p in NPC cells, which further supports our understanding of the mechanism underlying miR-34c-5p in NPC. Moreover, a previous study indicated that EGFR-PKM2 signalling promotes the malignant behaviour of NPC cells via the inactivation of FOSL1 and ANTXR2 [36], consistent with our results herein. EGFR is known to be the key promoter of multiple cancers (e.g. NSCLC, breast cancer [37–39]), and FOSL1 has been confirmed to be indirectly targeted by circCRIM1. Thus, circCRIM1 might act as the promoter of the EGFR pathway, and we plan to investigate the relationship between circCRIM1 and the EGFR pathway in the future.

Indeed, this study does have the following limitations: (1) more miRNAs downstream of circCRIM1 in NPC need to be explored, and (2) additional targets of miR-34c-5p in NPC remain unexplored. Thereafter, more analysis is necessary in the future.

**Conclusion**

This research was limited by the lack of in vivo experiments, which are needed to further validate the results. Thus, more investigations are needed in the future.

In conclusion, silencing circCRIM1 significantly attenuated the development of NPC through the miR-34c-5p/FOSL1 axis. Therefore, our study might shed new light on exploring new strategies for NPC treatment.

**Abbreviations**

circCRIM1: circRNA cysteine-rich transmembrane bone morphogenetic protein-regulator 1; FOSL1: Fos-like antigen-1; NPC: Nasopharyngeal carcinoma; AP-1: Transcription factor activator protein-1.

**Acknowledgements**

None.

**Authors’ contributions**

XZ and WH contributed to conceptualization, methodology, writing—original draft preparation, investigation and writing—reviewing and editing. YM contributed to software, validation, visualization and data curation. XT was involved in conceptualization, writing—original draft preparation, supervision and writing—reviewing and editing. All the authors read and approved the final manuscript.

**Funding**

This work was supported by grants from Changsha Science and Technology Bureau (kq2004104) and Natural Science Foundation of Hunan Province (2019JJ40159).

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

This article does not contain any studies with human participants or animals performed by any of the authors.

**Consent for publication**

Not applicable.

**Competing interests**

The author declared no competing interests in this study.

**Author details**

1 Oncology Department, The Second People’s Hospital of Hunan Province, Changsha 410007, Hunan, People’s Republic of China. 2 Oncology Department, Affiliated Nanhua Hospital of University of South China, No. 336 Dong Feng South Road, Hengyang 421002, Hunan, People’s Republic of China. 3 Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410013, Hunan, People’s Republic of China. 4 Oncology Department, The First Affiliated Hospital, University of South China, Hengyang 421001, Hunan, People’s Republic of China.

Received: 3 December 2021 Accepted: 23 February 2022

**References**

1. Zou R, Yuan J, Li Q, Ding JW, Liao B, Tu ZW, et al. The clinical outcomes and toxicities of induction chemotherapy followed by concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol. 2020;10:619625.

2. Miao X, Deng Z, Wang S, Weng H, Zhang X, Li H, et al. IAP-1 promoted cisplatin resistance in nasopharyngeal carcinoma via inhibition of caspase-3-mediated apoptosis. Am J Cancer Res. 2021;11(3):640–67.

3. Paliak S, Yaici G, Dolgun A, Ozgen B. The evolution of bone marrow signal changes at the skull base in nasopharyngeal carcinoma patients treated with radiation therapy. Radiol Med. 2021;126(6):818–26.
4. Zheng W, Ye W, Wu Z, Huang X, Xu Y, Chen Q, et al. Identification of potential plasma biomarkers in early-stage nasopharyngeal carcinoma-derived exosomes based on RNA sequencing. Cancer Cell Int. 2021;21(1):185.

5. Liu C, Guo F, Zhou L, Wang Y, Tian S, Ding Y, et al. A practical method to screen and identify functioning biomarkers in nasopharyngeal carcinoma. Sci Rep. 2021;11(1):7294.

6. Nan A, Chen L, Zhang N, Jia Y, Li X, Zhou H, et al. Circular RNA circNOL10 inhibits lung cancer development by promoting SCLM1-mediated transcriptional regulation of the humanin/peptide family. Adv Sci. 2019;6(27):1800654.

7. Qin C, Liu CB, Yang DG, Gao F, Zhang X, Zheng C, et al. Circular RNA expression alteration and bioinformatic analysis in rats after traumatic spinal cord injury. Front Mol Neurosci. 2018;11:497.

8. Fu B, Zhang A, Li M, Pan L, Tang W, An M, et al. Circular RNA profile of breast cancer brain metastasis identification of potential biomarkers and therapeutic targets. Epigenomics. 2018;10(12):1619–30.

9. Zheng S, Gu T, Bao X, Sun J, Zhao J, Zhang T, et al. Circular RNA hsa_circ_0013434 may serve as a diagnostic biomarker for essential hypertension. Exp Ther Med. 2019;17(3):1728–36.

10. Huang W, Song W, Jiang Y, Chen L, Lu H. c-Myc-induced circ-NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the mir-34c-5p/mi-Cyc axis. Cell Biol Int. 2021;45(7):1346–57.

11. Pan JY, Bao XL, Zhu K. Circular RNA LARP4 inhibits cell proliferation and invasion of nasopharyngeal carcinoma by repressing ROCK1. Eur Rev Med Pharmacol Sci. 2020;24(24):12624.

12. Hong X, Liu N, Liang Y, He Q, Yang X, Lei Y, et al. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1. Mol Cancer. 2020;19(1):33.

13. Shin JH, Shin DH, Kim JS. Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposomop for breast cancer stem cells. Asian J Pharm Sci. 2020;15(4):472–81.

14. Guo X, Luo Z, Xua T, Wu L, Shi Y, Li Y. Identification of miRNA signature associated with BMP2 and chemoresistance of TMZ in glioblastoma stem-like cells. Genes Dis. 2020;7(3):424–39.

15. Zhong Q, Huang J, Wei J, Wu R. Circular RNA CDR1as sponges miR-7-5p to enhance EZF2 stability and promote the growth of nasopharyngeal carcinoma. Cancer Cell Int. 2019;19:252.

16. Zhang Y, Liu Q, Liao Q, CichICPK3: a promising cancer-related circular RNA. Am J Transl Res. 2020;12(10):6694–704.

17. Li M, Li Y, Yu M. Circular RNA ZNF609 knockdown suppresses cell growth via modulating miR-186/EF2 axis in nasopharyngeal carcinoma. Oncol Targets Ther. 2020;13:2399–409.

18. Xu X, Yan H, Zhang L, Liu J, Huang Y, Cheng H. Up-regulation of miR-34c-5p inhibits nasopharyngeal carcinoma cells by mediating NOTCH1. Biosci Rep. 2020.

19. Nikitin CR, Xia S, Menden H, Wu Y, Xiong M, Heruth DP, et al. FOSL1 is a novel mediator of endotoxin/ILP6/polyasaccharide-induced pulmonary angiogenic signaling. Sci Rep. 2020;10(1):13143.

20. Evelin S, Galvagni F, Zippa A, Neri F, Orlandini M, Incarnato D, et al. FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of alphav and beta3 integrin transcription. Mol Cell Biol. 2013;33(16):11986–209.

21. Shen S, Li K, Liu Y, Liu X, Liu B, Ba Y, et al. Silencing IncRNA AGAP2-AS1 upregulates miR-195-5p to repress migration and invasion of EC cells via the decrease of FOSL1 expression. Mol Ther Nucleic Acids. 2020;20:331–44.

22. Elangovan IM, Vaz M, Tamatam CR, Potteti HR, Reddy NM, Reddy SP. FOSL1 promotes Kras-induced lung cancer through amphiregulin and cell survival gene regulation. Am J Respir Cell Mol Biol. 2018;58(5):625–35.

23. Vuletic A, Konjevic G, Milanicov D, Ruzdijic S, Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in GO/G1 arrested HL-60 cells. Pathol Oncol Res. 2010;16(3):393–401.

24. Radenkovc S, Konjevic G, Nikitovic M, Stojanovic Rundic S, Plesnicar Karapandzic V, Milovic Kovacevic M, et al. Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients. J BUON. 2021;26(2):475–82.

25. Ferri C, Di Bases A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, et al. miR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. J Exp Clin Cancer Res. 2022;41(1):20.

26. Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y, et al. Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. PLoS ONE. 2013;8(12):e84486.

27. Luo Z, Zhang L, Li X, Li G, Yu H, et al. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012;5:3.

28. Liu D, Liu W, Chen X, Yin J, Ma L, Liu M, et al. circCINKN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. Clin Transl Med. 2022;12(1):e662.

29. Zhang Q, Wang Z, Cai H, Guo D, Xu W, Su S, et al. CircPTK1 acts as a carcinogenic driver to promote the development of malignant pleural mesothelioma by governing the miR-1294/HMGA1 pathway. Biochem Genet. 2022.

30. Liu J, Feng G, Li Z, Li R, Xia P. Knockdown of CircCRIM1 inhibits HDAC4 to impede osteosarcoma proliferation, migration, and invasion and facilitate autophagy by targeting miR-432-5p. Cancer Manag Res. 2020;12:10199–210.

31. Kahl I, Mense J, Finke C, Bolzer A, Lorber C, Gyorffy B, et al. The cell cycle-related genes RHAMM, ALRUKA, TPX2, PLK1, and PLK4 are associated with the poor prognosis of breast cancer patients. J Cell Biochem. 2022.

32. Shen Z, Sun S. CircPTK1C1 promotes migration in lung cancer by repressing MYC expression through miR-34c-5p. Onco Targets Ther. 2021;14:4779–89.

33. Wang X, Zhu X. Tumor forkhead box Q1 is elevated, correlates with increased tumor size, international federation of gynecology and obstetrics stage but worse overall survival in epithelial ovarian cancer patients. Cancer Biother Radiopharm. 2021.

34. Wan Y, Hoyle RG, Xie N, Wang W, Cai H, Zhang M, et al. A super-enhancer driven by FOSL1 controls miR-21-5p expression in head and neck squamous cell carcinoma. Front Oncol. 2021;11:656628.

35. Yukimoto R, Nishida N, Hata T, Fujino S, Oginot T, Miyoshi N, et al. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. Cancer Sci. 2021;112(7):2884–94.

36. Chen S, Youhong T, Tan Y, He Y, Ban Y, Cai J, et al. EGFR-PK2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2. Carcinogenesis. 2020;41(6):723–33.

37. Shiri I, Amini MA, Nazari M, Hajianfar G, Haddadi Avval A, Abdollahi H, et al. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images. Comput Biol Med. 2022;142:105230.

38. Fang J, Li S, Zhang B, Duan N, Zhou R, Yan S, et al. FGFC1 exhibits anti-cancer activity via inhibiting NF-kappaB signaling pathway in EGFR-Mutant NSCLC cells. Mar Drugs. 2022;20(1):76.

39. Lieser RM, Li Q, Chen W, Sullivan MO. Incorporation of endosomolytic peptides with varying disruption mechanisms into EGFR-Targeted protein conjugates: the effect on intracellular protein delivery and EGFR imaging. Comput Biol Med. 2022;142:105230.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more: biomedcentral.com/submissions